Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists for bradykinin mediated diseases. Harnessing established science, the company aims to deliver oral bradykinin B2 receptor antagonists to help address unmet needs and improve standard of care. Our legacy, scientific expertise, and values drive our passion as we aspire to provide choice to people living with bradykinin-mediated diseases.
Looking for a particular Pharvaris employee's phone or email?
The Pharvaris annual revenue was $104.2 million in 2026.
Berndt Modig is the Co-founder and CEO of Pharvaris.
119 people are employed at Pharvaris.
The NAICS codes for Pharvaris are [5417, 541713, 325, 541, 54, 54171, 32, 3254].
The SIC codes for Pharvaris are [28, 87, 2834, 283].